Cara Therapeutics, Inc. is a development-stage biopharmaceutical company. Co. is focused on treatment paradigm to improve the lives of patients suffering from chronic pruritus. It is developing an oral formulation of difelikefalin, a selective, predominantly peripherally acting, non-scheduled Kappa opioid receptor agonist, for the treatment of chronic neuropathic pruritus associated with Notalgia Paresthetica (NP), a common, underdiagnosed neuropathy affecting the upper back. It is conducting Phase II/III Clinical Program in NP. We show 3 historical shares outstanding datapoints in our TVRD shares outstanding history coverage, used to compute TVRD market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing TVRD market cap history over the course of time is important for investors
interested in comparing TVRD's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of TVRD versus a peer is one thing; comparing
TVRD market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like TVRD can fluctuate over the course of history.
With this page we aim to empower investors researching TVRD by allowing them to research the TVRD market cap history. |
Free TVRD Email Alerts:
Video: The Importance of Market Cap
